[Urological therapy of renal cell cancer].
Renal cell carcinomas, which originate within the renal cortex, constitute 80-85% of primary renal neoplasms. Patients can present with a range of symptoms due to the tumor itself (e.g., mass, pain), invasion of the urinary tract (e.g., hematuria), paraneoplastic syndromes, or the presence of metastases. Renal cell cancer is more frequently being diagnosed incidentally as a consequence of increased use of imaging procedures for other reasons. Surgery is curative in the majority of patients without metastatic disease and is therefore the preferred treatment for patients with stages I, II, and III disease. The five-year survival following the treatment correlates well with the anatomic extent of disease. Systemic therapy with molecularly targeted therapy or immunotherapy is the primary approach for patients with unresectable or recurrent disease.
Ferber
Wolfgang
W
Abteilung für Urologie und Andrologie des Krankenhauses der Barmherzigen Brüder Wien, Wien, Austria.
Schramek
Paul
P
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001317:Austria; D002292:Carcinoma, Renal Cell / Q000175:diagnosis / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D003952:Diagnostic Imaging; D018572:Disease-Free Survival; D016503:Drug Delivery Systems; D005260:Female; D006801:Humans; D007167:Immunotherapy; D033162:Incidental Findings; D007672:Kidney Cortex / Q000473:pathology; D007680:Kidney Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D010535:Laparoscopy / Q000379:methods; D008297:Male; D008875:Middle Aged; D009392:Nephrectomy / Q000379:methods*; D016879:Salvage Therapy
D000970:Antineoplastic Agents